Awakn Life Sciences Income Statement

Financials in millions CAD. Fiscal year is February - January.

Millions CAD. Fiscal year is Feb - Jan.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '24 Oct 31, 2024	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Revenue	0.06	0.09	-	0.24	-
Cost of Revenue	-	-	-	0.51	-
Gross Profit	0.06	0.09	-	-0.28	-
Selling, General & Admin	1.54	2.35	3.28	4.94	0.77
Research & Development	0.73	0.83	1.36	3.31	-
Operating Expenses	2.48	4.01	5.28	9.52	0.84
Operating Income	-2.42	-3.93	-5.28	-9.79	-0.84
Interest Expense	-	-	-	-0.21	-0.01
Interest & Investment Income	0.01	0.09	0.31	-	-
Currency Exchange Gain (Loss)	-0.18	0.17	0.02	-0.06	0.01
Other Non Operating Income (Expenses)	0.27	-	-0	-5.28	-
EBT Excluding Unusual Items	-2.32	-3.67	-4.96	-15.33	-0.85
Merger & Restructuring Charges	-	-	-	-	-0.63
Other Unusual Items	-	-	-	-1.14	-
Pretax Income	-2.6	-3.67	-4.96	-16.47	-1.48
Earnings From Continuing Operations	-2.6	-3.67	-4.96	-16.47	-1.48
Earnings From Discontinued Operations	0.38	-1.34	-4.19	-	-
Net Income to Company	-2.22	-5.01	-9.14	-16.47	-1.48
Minority Interest in Earnings	-	-	-	0.53	0.22
Net Income	-2.22	-5.01	-9.14	-15.95	-1.26
Net Income to Common	-2.22	-5.01	-9.14	-15.95	-1.26
Shares Outstanding (Basic)	38	29	25	22	13
Shares Outstanding (Diluted)	38	29	25	22	13
Shares Change (YoY)	43.03%	15.34%	14.75%	73.91%	-
EPS (Basic)	-0.06	-0.17	-0.36	-0.73	-0.10
EPS (Diluted)	-0.06	-0.17	-0.36	-0.73	-0.10
Free Cash Flow	2.25	-2.38	-7.36	-10.29	-0.9
Free Cash Flow Per Share	0.06	-0.08	-0.29	-0.47	-0.07
Gross Margin	100.00%	100.00%	-	-117.28%	-
Operating Margin	-4235.11%	-4493.94%	-	-4149.34%	-
Profit Margin	-3876.53%	-5735.79%	-	-6755.65%	-
Free Cash Flow Margin	3939.36%	-2725.57%	-	-4358.76%	-
EBITDA	-2.4	-3.91	-4.88	-9.73	-0.84
D&A For EBITDA	0.02	0.02	0.4	0.06	0
EBIT	-2.42	-3.93	-5.28	-9.79	-0.84
Revenue as Reported	0.06	0.09	-	0.24	-

Updated Dec 13, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.